Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs News provided by Share this article - Stage I research programs designed to study how electro-modulation communicates to cells - Program objective to d and generating cellular response agreement EMED and Nazarbayev plan to begin the IDE process with the FDA SCOTTSDALE, Ariz., June 3, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+®, is pleased to announce that the Company recently completed an agreement with Nazarbayev University to expand its Stage I collaborative research programs. These Stage I programs will study how electro-modulation communicates to cells by modifying intracellular signaling events and altering physiological cellular response.